Current Status of Compounding of Semaglutide: With respect to the current status of compounding of semaglutide, FDA noted that it wished to avoid unnecessary disruption to patient treatment, and outlined the current enforcement policy moving forward: [T]he agency does not intend to take action against compounders for violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) arising from conditions that depend on semaglutide injection products inclusion on FDAs drug shortage list: For a state-licensed pharmacy under section 503A of the FD&C Act compounding, distributing or dispensing semaglutide injections within 60 calendar days from todays announcement, until
Learn more about Ammonium Polyacryloyldimethyl Taurate Vinyldimethicone is a type of silicone
Focus on long-term trends, not daily weigh-ins, to avoid unnecessary frustration
What are the main requirements for getting weight loss injections covered
4 The FDA approved the Wegovy pill for weight loss on December 22, 2025 and its expected to be available to patients in early January 2026
Insurance Coverage and Co-Pay Assistance Many people rely on insurance or manufacturer discount programs to afford expensive medications